Divis Laboratories
BSE: 532488 | NSE: DIVISLAB | ISIN: INE361B01024 | SECTOR: Biotechnology & DrugsOpen
3,435.05High
3,520.00Low
3,426.25Prev Close
3,385.95P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
929.94BVolume
23.69KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
-Ask
-
Company Description
- Biotechnology & Drugs
BSE
532488NSE
DIVISLABISIN
INE361B01024
Divi's Laboratories Limited is an India-based company, which is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).
Company Officers
Kiran Divi
Chief Executive Officer, Whole-time DirectorL. Kishore Babu
Chief Financial OfficerM. Satish Choudhury
Chief Compliance Officer, Company SecretaryMurali Divi
Managing Director, Executive DirectorMadhusudana Divi
Whole-Time Director (Projects)Nilima Divi
Whole-Time Director (Commercial)Nimmagadda Ramana
Executive Director